Am Heart J. 2016 Jun;176:63-9. doi: 10.1016/j.ahj.2016.01.016. Epub 2016 Jan 28.
The Cholesterol Treatment Trialists' (CTT) Collaboration was originally established to conduct individual participant data meta-analyses of major vascular events, cause-specific mortality, and site-specific cancers in large, long-term, randomized trials of statin therapy (and other cholesterol-modifying treatments). The results of the trials of statin therapy and their associated meta-analyses have shown that statins significantly reduce the risk of major vascular events without any increase in the risk of nonvascular causes of death or of site-specific cancer, but do produce small increases in the incidence of myopathy, diabetes, and, probably, hemorrhagic stroke. The CTT Collaboration has not previously sought data on other outcomes, and so a comprehensive meta-analysis of all adverse events recorded in each of the eligible trials has not been conducted. This protocol prospectively describes plans to extend the CTT meta-analysis data set so as to provide a more complete understanding of the nature and magnitude of any other effects of statin therapy.
胆固醇治疗试验协作组（CTT）最初成立的目的是，在他汀类药物治疗（以及其他胆固醇调节治疗）的大型长期随机试验中，对主要血管事件、特定病因死亡率和特定部位癌症进行个体参与者数据的荟萃分析。他汀类药物治疗试验及其相关荟萃分析的结果表明，他汀类药物可显著降低主要血管事件的风险，而不会增加非血管性死亡原因或特定部位癌症的风险，但确实会使肌病、糖尿病以及可能的出血性中风的发生率略有增加。CTT协作组此前未收集其他结局的数据，因此尚未对每项符合条件的试验中记录的所有不良事件进行全面的荟萃分析。本方案前瞻性地描述了扩展CTT荟萃分析数据集的计划，以便更全面地了解他汀类药物治疗的任何其他效应的性质和程度。
